arrow
M

Mimi I. Hu

湖北大学
H指数:43
被引数:6,277

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Lenvatinib plus pembrolizumab for the Treatment of Patients with Non-BRAF mutated Anaplastic Thyroid Cancer: A single center, phase 2 clinical trial,

仑伐替尼联合帕博利珠单抗治疗非BRAF突变的未分化甲状腺癌患者:一项单中心、II期临床试验

2026-08-260
OA
Segmental Tracheal Resection for Thyroid Cancer: Perioperative Morbidity, Locoregional Control, and Survival

甲状腺癌的节段性气管切除术:围手术期并发症、局部区域控制和生存率

2025-10-010
OAAI
Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in RET-Mutant Medullary Thyroid Cancer

患者报告的Selpercatinib耐受性对比卡博赞尼/Vandetanib:一项针对RET突变髓样甲状腺癌的LIBRETTO-531随机对照试验的二次分析

Thyroid
IF6.7
2025-08-180
PRE